Despite great enthusiasm for biomarkers as tools to enhance risk prediction and to lead the way in a transformation towards personalized cardiovascular medicine, progress in the biomarker field has been painstakingly slow, particularly in the area of population screening. Some individual biomarkers such as C-reactive protein (CRP) have demonstrated consistent associations with incident cardiova...

To the Editor: Wang et al. (Dec. 21 issue)1 suggest that novel biomarkers in aggregate have little influence on the prediction of first cardiovascular events or death. We wonder whether there were sufficient analyses to warrant this conclusion. As described, there were only 68 “major” cardiovascular events in women and 101 in men. In the crucial multimarker analyses, a quarter of these events w...

The aim of this study is whether oxidative stress markers, homocysteine (Hcy), cardiac troponin I (cTnI) and the activity of adenosine deaminase (ADA) alter following administration of different doses of sertraline. Sixty male Wistar rats were assigned into four groups. Sertraline at doses of 20, 40 and 80 mg / kg / day) were administered to three groups through gastric gavage for 90 days. The ...

Cardiovascular diseases are among the leading causes of morbidity and mortality. Despite scientific and technical progress in risk prediction, diagnostics, prognostication and therapy of cardiovascular pathologies, new biomarkers and therapeutic targets remain the subject of intense research to reduce the burden of these diseases. High throughput analyses, termed "omics", are a promising avenue...